Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma

Mikael Kerboeuf1*, Erling Olaf Koppang2, Anita Haug Haaland1, Frode Lingaas2, Øyvind Sverre Bruland3, Jon Teige2 and Lars Moe1

Abstract

Background: Despite decades of research, the early phases of metastatic development are still not fully understood. Canine osteosarcoma (OS) is a highly aggressive cancer, with a high metastatic rate (> 90%), despite a low overt metastatic prevalence at initial diagnosis (< 15%). Canine OS is generally regarded as a good clinically relevant model for human OS. The aim of this hypothesis-generating study was to evaluate a method to detect pulmonary micrometastases and study their prevalence in dogs with OS without macroscopic metastases. We prospectively enrolled dogs with OS that received no cancer-specific treatment (n = 12) and control dogs without cancer (n = 2). Dogs were necropsied and sampled immediately after euthanasia. The OS dogs were classified as having macroscopic metastases (n = 2) or not (n = 10). We immunohistochemically stained one tissue sample from each of the seven lung lobes from each dog with a monoclonal antibody (TP-3) to identify micrometastases (defined as clusters of 5–50 tumour cells), microscopic metastases (> 50 tumour cells) and TP-3 positive single cells (< 5 tumour cells).

Results: We showed that pulmonary micrometastases easily overseen on routine histology could be detected with TP-3. Pulmonary micrometastases and microscopic metastases were present in two dogs with OS without macroscopic metastases (20%). Micrometastases were visualised in three (43%) and four (57%) of seven samples from these two dogs, with a mean of 0.6 and 1.7 micrometastases per sample. Microscopic metastases were present in one (14%) and four (57%) of seven samples from the same two dogs, with a mean of 0.14 and 1.0 microscopic metastases per sample. There were four (57%) and two (29%) samples with neither microscopic metastases nor micrometastases for each of these two dogs. The prevalence of pulmonary micrometastases (20%) was significantly lower than expected (> 90%) based on commonly expected metastatic rates after amputation (P < 0.0001). There was no statistically significant difference in the number of TP-3 positive single cells in between groups (P = 0.85).

Conclusions: Pulmonary micrometastases could be detected with TP-3 immunohistochemistry in a subset of dogs with OS before macroscopic metastases had developed. We propose that dogs with spontaneous OS represent clinically relevant models to study early micrometastatic disease.

Keywords: Bone cancer, Canine, Lung metastasis, Metastasis model, Pulmonary metastasis
This is especially true when developing new therapeutics, as the majority have failed to reach the clinic. Micrometastases have been studied in some spontaneous canine cancer forms [8–12]. Their presence in lymph nodes, peripheral blood and bone marrow has been investigated in dogs with mammary carcinoma, as well as in lymph nodes of dogs with some other carcinomas and mast cell tumours. In humans, micrometastases have been studied in lymph nodes, bone marrow, lungs, liver, pleural or peritoneal cavities and peripheral blood in several forms of cancer [13–22].

Spontaneous canine osteosarcoma (OS) is considered a good model for human OS [23–30]. Most dogs with OS succumb to the disease, with the majority dying or being euthanized due to metastatic disease [31]. Although radiographically detectable metastases are uncommon at presentation (<15–17%), most dogs eventually develop metastatic disease (>90%) [31–35]. A question that remains unanswered is where the disseminated cells reside before macroscopic metastases develop. The main target organs for metastatic OS, both in humans and dogs, are the lungs and bones [29, 31, 34–37]. Bruland et al. found tumour cells in the bone marrow in 63% of human OS patients at presentation [14]. Amongst those presenting with overt metastases, the prevalence of tumour cells in the bone marrow was 92%. To our knowledge, micrometastases in the lungs have not been prospectively investigated either in human or canine OS.

The monoclonal antibody TP-3 binds selectively to a sarcoma-associated cell surface membrane antigen related to osteoblastic differentiation [38, 39]. The antigen is a monomeric polypeptide with alkaline phosphatase activity and a molecular weight of 80 kDa. TP-3 has been shown to bind to all evaluated OS cases in dogs [40, 41]. Similarly, various human sarcomas express the antigen, including all human OS cases examined [38, 39].

The aim of this hypothesis-generating study was to evaluate the use of TP-3 immunohistochemistry (IHC) on frozen tissue sections as a tool to detect pulmonary micrometastases and to study their prevalence in dogs with spontaneous OS before the development of macroscopic metastasis.

**Methods**

**Study population**

This study was conducted as a prospective case series of necropsied dogs with OS (OS+) and control dogs without OS (OS−). All cases were privately owned dogs presented to the Veterinary Teaching Hospital and private practices. Owners signed a participation consent form before the dogs were euthanized and necropsied. Dogs included in the OS+ group could be of any breed, sex and age, had to have an appendicular primary tumour location and a confirmed histopathological OS diagnosis. Dogs that had undergone surgical treatment, except for diagnostic incisional biopsies, or other treatments except for pain-relieving drugs (opioids and NSAIDs), were excluded. For inclusion into the OS− group, dogs could be of any breed, sex and age, and had to have been euthanized for non-cancer-related disease. Hence, dogs with a previous history of cancer or a histopathological cancer diagnosis at necropsy were excluded from the OS− group.

**Necropsy and tissue collection**

According to our protocol, all dogs had to be necropsied within two hours after euthanasia. Standard necropsy procedure was followed, with all organ systems being inspected macroscopically. Based on necropsy results, dogs in the OS+ group were further classified as having macroscopic pulmonary metastases (OS+/Met+) or not (OS+/Met−). Tissue samples from all major organ systems (kidneys, lungs, liver, spleen, adrenal glands, myocardium, skeletal muscles and intestines) and any lesions suspected of being metastatic or neoplastic were collected and formalin-fixed. All formalin-fixed paraffin-embedded samples were stained with haematoxylin & eosin (H&E) and examined microscopically. Four tissue samples (sample size of approximately 1 × 1 cm) were taken from each of the seven lung lobes from each dog. Two were taken from the peripheral areas of the lobes, where only small bronchi were present, and two from the central, close to the main stem bronchi. Samples from all areas were collected for both formalin fixation and snap freezing in cold isopropanol (−20 °C), quickly followed by submersion in liquid nitrogen and storage at −80 °C. For dogs in the OS+/Met+ group, samples for IHC analysis were taken from the same anatomical regions while avoiding macroscopic metastases. In addition, tissue samples from macroscopic metastases were formalin-fixed, stained with H&E and examined microscopically. Six of the seven samples from the peripheral areas and one of the seven from the central were picked at random, using an online random number generator (www.random.org) for further IHC analysis.

**IHC staining**

IHC TP-3 staining was performed on frozen tissue sections. Snap frozen samples were sliced into 7 μm sections with a cryostat at −25 °C. The tissue sections were mounted on poly-lysine-coated slides (Superfrost™ Plus, Thermo Fisher Scientific, Oslo, Norway) and dried at room temperature for one hour. The slides were then stored at −80 °C until further preparation. IHC sections were labelled using the peroxidase-conjugated immune-polymer method (EnVision™, Dako, Glostrup, Denmark).
The sections were first fixed in cold acetone (−20 °C) for 10 min, followed by air-drying for 10 min. Endogenous peroxidase activity was inhibited by immersing the slides in a cold (4 °C) 0.3% H2O2 solution in phosphate-buffered saline (PBS) for 10 min. To prevent non-specific binding, the sections were blocked using a 1:50 solution of normal goat serum in 5% bovine serum albumin in tris-buffered saline (BSA/TBS) for 30 min. Sections were incubated with the purified IgG 2A monoclonal murine antibody (TP-3, 5 μg/mL, Norwegian Radiumhospital, Oslo, Norway), diluted in 1% BSA/TBS, for 60 min. The samples were then incubated with the secondary antibody (EnVision™, Dako, Glostrup, Denmark) for 30 min. Finally, immunolabelled tissues were developed using a 3-amin-9-ethylcarbazole (AEC) substrate chromogen (EnVision™, Dako, Glostrup, Denmark) incubated for 8 min, then counterstained with Mayer’s haematoxylin. The slides were mounted with coverslips using a water-soluble mounting medium (Aquatex®, Merck, Darmstadt, Germany) and left to dry at room temperature overnight. Negative controls were stained without primary antibodies. Tumour cells throughout all micrometastases and macroscopic metastases were used as a positive control for each staining.

**IHC analysis**

Each slide was scanned for microscopic metastases, micrometastases and TP-3 positive single cells. Micrometastases were defined as clusters of ≥5 and ≤50 TP-3 positive cells. Clusters >50 cells were defined as microscopic metastases, while clusters of <5 TP-3 positive cells were defined as TP-3 positive single cells.

IHC stained slides were evaluated using a Zeiss AX10 microscope, equipped with a Zeiss axicam 506 color camera, coupled with Zen pro 2012 (blue edition) image acquiring software (Carl Zeiss Microscopy GmbH, Jena, Germany). The total number of microscopic metastases and micrometastases, if present, were counted in the entire slide for each sample. The number of TP-3 positive single cells was counted in 10 high-power fields (HPF, defined as one field at 400x, equivalent to 0.196 mm2 for the microscope used). Areas with folded up tissue were excluded from the analysis. Slides where staining was too weak to identify positive cells or significant unspecific staining was present, were also excluded.

**Statistical analysis**

All statistical analyses were performed using JMP pro 15.1.0 (SAS Institute Inc., Cary, NC). The mean number of TP-3 positive single cells per 10 HPF per lung lobe was compared between groups using Wilcoxon rank-sum tests for each pair and an unpaired Kruskal–Wallis test. The mean number of TP-3 positive single cells per 10 HPF for the different lung lobes (anatomical division) was compared between all the dogs combined and in between groups using Wilcoxon rank-sum tests for each pair and an unpaired Kruskal–Wallis test. The prevalence of micrometastases was tested against the expected prevalence (>90%, based on the post-surgical metastatic rate) using a binomial test. P-values < 0.05 were considered statistically significant for statistical testing.

**Results**

**Study population**

Cases were enrolled and necropsied between 2012 and 2020. In total 14 dogs were included in the study, ten in the OS+/Met− group, two in the OS+/Met+ group and two in the OS−/Met− group (see Tables 1 and 2). OS+ cases were confirmed based on clinical signs, diagnostic imaging, and histopathologic examination after H&E staining. The mean age was 5.6 years (median six years, range 1–11 years). There were eight (57%) male and six (43%) female dogs. The mean time from clinical presentation to euthanasia due to OS was 33 days (median 9.5 days, range 1–155 days). No neoplastic disease other than OS was found at necropsy in any of the dogs. The only significant pathological changes in the lungs were the macroscopic metastases seen in the two OS+/Met+ dogs (Fig. 1a) and microscopic metastases (Fig. 1b) and suspected micrometastases (Fig. 1c) in some of the OS+/Met− dogs.

**Pulmonary micrometastases and microscopic metastases**

A total of 98 lung samples underwent IHC TP-3 staining and histological evaluation, in addition to the positive and negative controls. Tumour cells throughout all micrometastases and microscopic metastases showed a strong and seemingly cytoplasmatic TP-3 staining, as seen in Fig. 2. Depending on their size, micrometastases were either found lodged within pulmonary arterioles (Fig. 2) or the capillaries of the alveolar septa. In larger metastatic lesions, TP-3 staining varied more. Here, cells in the periphery showed strong staining, while those towards the centre stained only weakly or not at all. Micrometastases were present in two dogs (20%) in the OS+/Met− group (Table 2), whereas we found none in the ten remaining cases (eight in the OS+/Met+ and both in the OS+/Met+ group) or the OS−/Met− group. Microscopic metastases were present in these same two dogs (Table 2). Micrometastases were found in three (43%) and four (57%) of the seven samples examined for each of the two dogs. The total number of micrometastases
in each dog was four and 12, respectively, with a mean of 0.6 (range 0–2) and 1.7 (range 0–6) micrometastases per sample. Microscopic metastases were found in one (14%) and four (57%) of the seven samples in the same two dogs. The total number of microscopic metastases was one and seven, respectively, with a mean of 0.14 (range 0–1) and 1.0 (range 0–3) microscopic metastases per sample. Figure 3 shows the distribution of metastases in each lung lobe. There were four (57%) and two (29%) samples for each of the two dogs with neither microscopic metastases nor micrometastases.

TP-3 positive single cells

TP-3 positive single cells were present in the lung parenchyma in all samples in all dogs. These were either scattered respiratory epithelial cells or metastatic OS cells. Most TP-3 positive single cells were identified as dislodged respiratory epithelium, based on cytoplasmatic morphology, staining pattern and nuclear characteristics (Fig. 4). They showed asymmetrical staining, which was stronger along the ciliated brush border and weaker on the opposite side of the cell. In addition, the majority had small to moderately sized eccentric nuclei and no visible nucleoli. In some cases, TP-3 positive single cells were more compatible with tumour cells, showing a strong and homogenous cytoplasmatic staining, with large nuclei and distinct nucleoli (Fig. 5). In most cases, we could not reliably distinguish the two cell populations, and as such, they were all counted as TP-3 positive single cells.

The mean number of TP-3 positive single cells per 10 HPF per sample was 6.5 (median 6.5, range 5.9–7) for the OS+/Met+ group, 120.5 (median 15.2, range 3–941.9) for the OS+/Met− group and 17.9 (median 17.9, range 4.7–31.1) for the OS−/Met− group. There was no statistically significant difference in the mean number of TP-3 positive single cells per 10 HPF per sample between the groups (P = 0.85). There was no statistically significant difference between the means of the OS+/Met− group and the OS+/Met+ (P = 0.75) or OS−/Met− (P = 0.75) group, nor between the OS+/Met+ and OS−/
Met− group (P = 1.0). There were no statistically significant differences in the mean number of TP-3 positive single cells per 10 HPF between any of the different lung lobes (anatomical division), neither when combining all the dogs (P = 0.96), nor within the different groups (for OS+/Met+, P = 0.82, OS+/Met−, P = 0.89 and OS−/Met−, P = 0.62).

**Normal structures stained with TP-3**

TP-3 staining was observed on the luminal side of the bronchial and bronchiolar epithelium in all dogs (Fig. 6). Staining of the epithelium in the terminal and respiratory bronchioles and alveolar ducts was more variable amongst dogs. In most cases, the staining was weak at the level of the terminal and respiratory bronchioles, with no visible staining towards the alveolar ducts. The columnar respiratory epithelium showed an asymmetrical staining pattern, as described for the dislodged respiratory epithelium (Fig. 6). The cuboidal epithelium of the respiratory and terminal bronchioles was more evenly stained throughout the cytoplasm and with a weaker intensity. Also, the bronchial seromucous glands showed asymmetrical cytoplasmatic staining in all dogs, with a stronger staining intensity towards the luminal side.
Discussion

To further improve OS treatment strategies and outcomes, it is essential to understand the pathogenesis of metastasis. In this hypothesis-generating study, we have shown that it is feasible to identify pulmonary micrometastases in dogs with OS using IHC with the monoclonal antibody TP-3. All cases of canine OS previously examined with TP-3 have shown positive staining of the primary tumour [40, 41]. In the present study, we found that pulmonary metastases, microscopic metastases and micrometastases also bind TP-3. We found pulmonary micrometastases and microscopic metastases in only...
20% of the dogs with OS before macroscopic metastases had developed. This was less than expected, seeing as most dogs with OS (> 90%) eventually develop pulmonary metastases, despite few having detectable metastases at presentation (< 15–17%) [31, 34, 35, 42].

One of the main concerns when using morphological methods such as IHC to detect micrometastases is that only a small portion of the entire lung can be examined. We found that micrometastases were present in three (43%) and four (57%) of the seven lung lobes examined. This finding seemingly indicates that the micrometastatic burden is relatively high once micrometastases have developed. However, our protocol might not be sensitive enough to identify dogs with a lower micrometastatic burden. It was not the scope of this study to examine the entire lung to find the true prevalence or distribution of micrometastasis. This would require the use of other methods of investigation. Without this information, we cannot evaluate the location from where tissue preferably should be sampled, nor the number of samples needed to reliably classify dogs as having micrometastases or not. Another possible explanation for the low incidence of pulmonary micrometastases could be that the lungs are not the primary site for metastatic dissemination during the early phases of metastasis in dogs with OS.

Among human patients with OS, the prevalence of tumour cells in the bone marrow at presentation was 63% and seemingly correlated with outcome [14, 43]. This is substantially higher than the prevalence of pulmonary micrometastases reported here in OS dogs. A possible explanation could be that the bone marrow serves as a temporary nest for metastasized cells until the subsequent dissemination of tumour cells to the lungs. Indeed, it has been shown that tumour cells of prostate and breast cancer in humans can disseminate to the bone marrow using mechanisms similar to those used by homing hematopoietic stem cells [44–47]. It has been suggested that these tumour cells can lay dormant in the bone marrow niche, where they remain quiescent for several years until metastases develop [48, 49]. Further studies investigating the presence of micrometastases in other organs in dogs with OS, such as the bone marrow, are therefore warranted.

We found no micrometastases or microscopic metastases in the two dogs in the OS+ /Met+ group (Table 2). Samples were taken from the same anatomical locations of the lungs as from the other dogs in the study, but specifically from tissues without macroscopic metastases. However, both dogs had a low metastatic burden (a total of 2 and 7 macroscopic metastases), which could indicate a less aggressive tumour phenotype. This might seem counterintuitive, as we might expect a higher micrometastatic burden once macroscopic metastases are present. However, the inhibitory effect of primary tumours on the growth of metastases is not an unknown phenomenon [50–52]. Whether overt lung metastases could exhibit a similar inhibitory effect on micrometastatic development is unknown, and further studies are needed to shed light on this. In a study evaluating the prevalence of micrometastases in seemingly unaffected areas of the lung in humans with primary lung cancer, the authors found that 47% had micrometastases [19]. Although they
investigated a different cancer disease, they used a morphological method as well. They found that only 7.7% of the examined microscopic slides contained micrometastases, emphasizing the need to evaluate several samples per patient. Similarly, the prevalence of hepatic micrometastases was investigated at metastasectomy in humans with ileal, small intestinal and pancreatic neuroendocrine tumours and colorectal cancer [20–22]. The authors found micrometastases in 100, 67, 32 and 56% of patients, respectively, in seemingly unaffected liver tissue. It appears that the presence of macroscopic metastases is no guaranty for finding micrometastases when using morphological methods to detect them.

TP-3 has not been commercially available since its discovery, and there is a limited number of studies that have used the antibody. In the veterinary field, there are only two [40, 41]. In contrast to the membrane staining seen in humans, we found that TP-3 staining of tumour cells also had a cytoplasmatic distribution [38]. The previously reported staining of the brush border of ciliated epithelial cells in the bronchi and lungs of dogs, not seen in humans, corresponded well with our observations [40]. The TP-3 staining of the seromucous glands has not been described previously. This lack of specificity was not an issue when detecting micrometastases and microscopic metastases. They were easily distinguishable from normal structures based on location, clustering of cells, nuclear and cytoplasmatic morphology and staining intensity.

The number of TP-3 positive single cells varied considerably between dogs. In one case, TP-3 staining of the epithelium was present from the bronchi to the alveolar ducts, resulting in high numbers of TP-3 positive single cells per 10 HPF (case 8). New sections from this dog were sliced and stained and with the same results. This staining variation, combined with the poor morphology and dislodgement of epithelium associated with frozen sections, makes TP-3 a poor IHC marker for pulmonary single-cell metastases in dogs with OS. In most cases, distinguishing single tumour cells from dislodged respiratory epithelial cells based on staining pattern and morphology was impossible. Formalin-fixed tissue would have offered better morphology, but formalin ablates the epitope of the TP-3 [38]. We have made several attempts to optimise a protocol for formalin-fixed paraffin embedded canine tissue, but with disappointing results. Most samples were chosen from the peripheral areas of the lung (6/7 samples) to reduce the amount of respiratory epithelium included. Since TP-3 stained the respiratory epithelium down to the bronchioles and sometimes into the smaller airways, this probably had no impact on the number of TP-3 staining non-tumour cells. There was no tendency towards higher numbers of TP-3 positive single cells in the OS+ groups. However, the number of dogs included is too small to draw any definite conclusions, and other methods should be considered when studying single-cell metastases.

Another limitation of our study is that the primary tumour was not IHC evaluated with TP-3. It is thus possible that some of the OS cases were TP-3 negative, and consequently, so would the micrometastases and microscopic metastases. Hence, this may have resulted in an underestimation of the micrometastatic prevalence. However, in the previous report investigating canine OS using TP-3, 13/13 tumours were TP-3 positive [40]. Likewise, in a study evaluating the use of TP-3 Fab fragments for positron-emitting tomography imaging in dogs with OS, binding was documented in the primary tumour in the four cases included [41]. In humans, 15/15 and 31/31 cases of OS examined using IHC showed strong TP-3 staining [38, 39]. There were no suspected micrometastases or microscopic metastases which did not stain with TP-3 among our dogs after careful microscopic examination of all samples.

Historically, micrometastases have been defined in different ways depending on the method of investigation and organ. When using morphological methods to identify micrometastases in lymph nodes (histology or IHC), they are generally defined as tumour cell clusters of > 0.2 mm but < 2 mm in diameter [13, 53, 54]. Clusters < 0.2 mm are usually classified as isolated (disseminated or circulating) tumour cells. Since there is no established definition for pulmonary micrometastases, we chose to define them as clusters of ≥ 5 and ≤ 50 tumour cells. Because IHC is a more sensitive method than H&E staining to identify micrometastases, we chose an upper limit of 50 cells. Clusters of > 50 cells are more easily detectable in H&E stained lung tissue, and we classified those as microscopic metastases.

Metastasis has been extensively studied in laboratory animals and in vitro models. The limited translational value of these models when developing new therapeutics has inspired researchers to create new and more sophisticated cancer models [7, 55]. Dogs with cancer have proven to be reliable clinically relevant models for human cancer, also when developing new therapeutics [56]. Given the seemingly low prevalence of pulmonary micrometastases and the fact that most eventually develop metastases, dogs with OS should serve as excellent spontaneous cancer models to study premetastatic niche formation [57]. This might include studying immunological, metabolic, and extracellular matrix changes in the lungs before metastasis has occurred. Rigorous prospective study designs and relevant controls are needed to accomplish this. If findings from murine models can be verified in a naturally occurring spontaneous cancer model such as the dog, it would further support the underlying
mechanisms of premetastatic niche formation observed in mice. Since many owners decline cancer-specific treatment, a significant proportion of dogs are euthanized at an early disease stage. These dogs are excellent candidates to study distant metastatic target organs early in the disease process, to an extent not feasible in humans. Furthermore, by verifying findings from murine models, dogs could serve as a bridge between the preclinical models and humans for developing new therapies targeting premetastatic niche formation. We propose that dogs with spontaneous appendicular OS could represent clinically relevant models for studying early micrometastasis and premetastatic niche formation as an addition to murine models.

Conclusions
Our data shows that pulmonary micrometastases can be detected in dogs with OS by using TP-3 immunohistochemistry. The prevalence of pulmonary micrometastases was significantly lower than expected in dogs with OS before macroscopic metastases had developed. Once present, the micrometastatic burden was relatively high. This could indicate that pulmonary metastases do not originate directly from the primary tumour. However, it remains a hypothesis-generating study, and larger studies are needed to validate our findings.

Acknowledgements
The present study was partly funded by the faculty of veterinary medicine, Norwegian University of Life Sciences, as well as by Oncoinvent AS, Oslo, Norway, SVFs professional and scientific fund, Oslo, Norway and The Research fund for cancer in dogs, Oslo, Norway. TP-3 antibodies were generously provided by Oncoinvent AS.

Prior publication
Data have not been published previously.

Authors’ contributions
MK participated in the collection of material, performed the immunohistochemical staining and examination of pulmonary tissue samples, analysed and interpreted the patient data and was a major contributor in writing the manuscript. EOK supervised the immunohistochemical staining, protocol validation, contributed to the study design and writing of the manuscript. AHH contributed to the study design and was a major contributor in writing of the manuscript. FL contributed to the study design, collection of material and writing of the manuscript. DSB contributed to the conception, design and immunohistochemical staining protocol, as well as writing the manuscript. JT performed the histological examination of all primary tumours, metastases, and routine histology examination. LWM contributed to the conception, design, interpretation of data and was a major contributor in writing of the manuscript. All authors have read and approved the final version of the manuscript.

Funding
The present study was partly funded by the faculty of veterinary medicine, Norwegian University of Life Sciences (which was also involved in design, collection of samples, analysis interpretation and writing of the manuscript), Oncoinvent AS, Oslo, Norway, SVFs professional and scientific fund, Oslo, Norway, and The Research fund for cancer in dogs, Oslo, Norway.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval
This study did not require official or institutional ethical approval. The animals were handled according to high ethical standards and national legislation.

Consent for publication
Owners signed a participation consent form before the dogs were euthanized and necropsied, allowing for publication of anonymized research results.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Elizabeth Stephansens vei 15, 1433 Ås, Norway. 2 Department of Preclinical Sciences and Pathology, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Elizabeth Stephansens vei 15, 1433 Ås, Norway. 3 Institute of Clinical Medicine & Faculty of Medicine, Department of Oncology, The University of Oslo & Norwegian Radium Hospital, Oslo University Hospital, Ullemausaven 70, 0379 Oslo, Norway.

Received: 28 July 2021 Accepted: 19 October 2021
Published online: 03 November 2021

References
1. Wang H, Naghavi M, Allen C, Barber RM, Bhatta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, Coggeshall M. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.
2. Adams VJ, Evans KM, Sampson J, Wood JLN. Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract. 2010;51:512–24.
3. Inoue M, Hasegawa A, Hosoi Y, Sugii A. A current table and causes of death for insured dogs in Japan. Prev Vet Med. 2015;120:210–8.
4. Bonnett BN, Eegenail A, Olson P, Hedhammar A. Mortality in insured Swedish dogs: rates and causes of death in various breeds. Vet Rec. 1997;141:40–4.
5. Proschowsky HF, Ruggiol H, Eggenschall AK. Mortality of purebred and mixed-breed dogs in Denmark. Prev Vet Med. 2003;58:63–74.
6. Dillekas H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8;5574–6.
7. Ireson CR, Alavie J, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121:101–8.
8. Matos AJ, Faustino AM, Lopes C, Rutemman GR, Gartner F. Detection of lymph node micrometastases in malignant mammary tumours in dogs by cytokeratin immunostaining. Vet Rec. 2006;158:626–30.
9. Szczubial M, Lopuszynski W. Prognostic value of regional lymph node status in canine mammary carcinomas. Vet Comp Oncol. 2011;9:296–303.
10. Weishaar KM, Thamm DH, Worley DR, Rasmussen DA. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. J Comp Pathol. 2014;151:329–38.
11. Casey KM, Steffen MA, Affolter VU. Identification of occult micrometastases and isolated tumour cells within regional lymph nodes of previously diagnosed non-metastatic (stage 0) canine carcinomas. Vet Comp Oncol. 2017;15:785–92.
12. Marconato L, Facchinetti A, Zanardiello C, Rossi E, Vidotto R, Capello K, et al. Detection and prognostic relevance of circulating and disseminated tumour cell in dogs with metastatic mammary carcinoma: a pilot study. Cancers. 2019;11:163–76.
13. Huivos AG, Hutter RV, Berg JW. Significance of auxiliary macrometastases and micrometastases in mammary cancer. Ann Surg. 1971;173:44–6.
14. Bruland OS, Hofstad H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11:4666–73.

15. Sloane JP, Ormerod MG, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res. 1980;40:3079–82.

16. Zhang XW, Yang HY, Fan P, Yang L, Chen GY. Detection of micrometastasis in peripheral blood by multi-sampling in patients with colorectal cancer. World J Gastroenterol. 2005;11:436–8.

17. Nakajima T, Harashima S, Hirata M, Kajitani T. Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol. 1978;22:225–9.

18. Kondo H, Naruie T, Tsuchiya R, Goya T, Suemasu K, Yamagishi K, et al. Pleural lavage cytology immediately after thoracotomy as a prognostic factor for patients with lung cancer. Jpn J Cancer Res Gann. 1989;80:233–7.

19. Hashimoto K, Takahashi T, Suzuki C. Micrometastasis in resected lungs of lung cancer patients. Gann. 1976;67:717–23.

20. Nanko M, Shimada H, Yamaoka H, Tanaka K, Masui H, Matsuo K, et al. Micrometastatic colorectal cancer lesions in the liver. Surg Today. 1998;28:707–13.

21. Gibson WE, Gonzalez RS, Cates JMM, Liu E, Shi C. Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. Hum Pathol. 2018;79:109–15.

22. Fossmark R, Balto TM, Martinsen TC, Grønbech JE, Munkvold B, Mjønes PG, et al. Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection. Scand J Gastroenterol. 2019;54:1003–7.

23. Morello E, Martano M, Butacca P. Biology, diagnosis and treatment of canine appendicular osteosarcoma: similarities and differences with human osteosarcoma. Vet J (Lond, Engl). 2011;189:268–77.

24. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res. 1997;338:159–68.

25. Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CO Jr. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, controlled, phase III trial. Vet Comp Oncol. 2016;14:81–7.

26. Brodey RS. The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J Biol Med. 1979;52:345–61.

27. Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Res. 2007;27:155–64.

28. Withrow SJ, Wilkins RM. Cross talk from pets to people: translational research into human cancer: general considerations and a review of canine osteosarcoma. J Vet Intern Med. 2008;22:995–9.

29. Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 2014;28:54–63.

30. Skorupska KA, Uhl JM, Szovek A, Allstadt Frazier SD, Rebhun RB, Rodriguez CO Jr. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial. Vet Comp Oncol. 2016;14:81–7.

31. Cavalcanti JN, Amstalden EMM, Guerra JL, Magna LC. Osteosarcoma in dogs: clinical-morphological study and prognostic correlation. Braz J Vet Res Anim Sci. 2004;41:299–305.

32. Ling GV, Morgan JP, Pool RR. Primary bone tumors in the dog: a combined clinical, radiographic, and histologic approach to early diagnosis. J Am Vet Med Assoc. 1974;165:55–67.

33. Brodey RS, Sauer RM, Medway W. Canine bone neoplasms. J Am Vet Med Assoc. 1963;143:471–95.

34. Federman N, Bemthal N, Elber FC, Tap WD. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 2009;10:822–93.

35. Bruland OS, Fodstad O, Stenwig AE, Pihl A. Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res. 1988;48:5302–9.

36. Bruland O, Fodstad O, Funderud S, Pihl A. New Monoclonal-Antibodies Specific for Human Sarcomas. Int J Cancer. 1986;28:27–31.

37. Haines DM, Bruland OS. Immunohistochemical detection of osteosarcoma-associated antigen in canine osteosarcoma. Anticancer Res. 1989;9:903–7.

38. Page RL, Garg PK, Garg S, Archer GE, Bruland OS, Zalutsky MR. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. J Nucl Med. 1994;35:1506–13.

39. Ehrtart NR, SD; Fan, TM. Tumors of the skeletal system. Withrow and MacEwen’s small animal clinical oncology, 5th edn. St. Louis, Missouri: Saunders, Elsevier; 2013. p. 463–503.

40. Bruland ØS, Hofstad H, Hall KS, Smeland S, Fodstad Ø. Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremely localized non-metastatic osteosarcoma patients. Cancer Treat Res. 2009;152:509–15.

41. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832–7.

42. Muller A, Horney B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.

43. Allocco G, Hughes R, Wang N, Brown HK, Ottewell PD, Brown NJ, et al. The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche in vivo. J Bone Oncol. 2019;17:100244.

44. Shiozawa Y, Eber MR, Berry JE, Taichman RS. Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. Bonekey Rep. 2015;4:689.

45. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834–46.

46. Paez D, Labonte MJ, Bohanes P, Zhang W, Benhamin L, Ning Y, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res. 2012;18:643–53.

47. Demicheli R, Retsky MW, Hirshesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19:1821–8.

48. Kaya M, Wada T, Nagoya S, Kawaguchi S, Isu K, Yamashita T. Concomitant tumour resistance in patients with osteosarcoma: A clue to a new therapeutic strategy. J Bone Joint Surg Br. 2004;86:143–7.

49. Tsunemi T, Nagoya S, Kaya M, Kawaguchi S, Wada T, Yamashita T, et al. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res. 2003;407:159–66.

50. Benson JR, Querci Della Rovere G. Classification of isolated tumor cells and micrometastasis. Cancer Am Cancer Soc. 2000;89:707–9 (author reply 11).

51. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast Cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:290–303.

52. Pate A, Whimble YE, Ting TL, Sowerwine RM, Whimble YE, Ting TL, et al. The use of preclinical models to validate new therapeutic targets in breast cancer. Clin Cancer Res. 2009;15:6786–94.

53. Doglioni G, Parik S, Fendt SM. Interactions in the (Pre)metastatic niche support metastasis formation. Front Oncol. 2019;9:219.

54. Ehrhart NR, SD; Fan, TM. Tumors of the skeletal system. Withrow and MacEwen’s small animal clinical oncology, 5th edn. St. Louis, Missouri: Saunders, Elsevier; 2013. p. 463–503.

55. Feng J, Plunkett W, Zhu S, O’Hara MJ, Vazquez F, Ackerman SR, et al. Cell surface antigen expression and micrometastasis. Cancer Am Cancer Soc. 2000;89:707–9 (author reply 11).

56. Dow S. A role for dogs in advancing cancer immunotherapy research. Review of Immunology. 2010;46:1–16.

57. Garrett WC. Animal models in osteosarcoma. Yale J Biol Med. 1979;52:345–61.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.